Does the SRD5A2 rs523349 (V89L) variant change DHT production?

The SRD5A2 gene plays a critical role in androgen metabolism by encoding the 5α-reductase type 2 enzyme, which facilitates the conversion of testosterone into dihydrotestosterone (DHT). Research into the rs523349 (V89L) polymorphism confirms that genetic variations in this gene directly impact the rate of this conversion and subsequent DHT levels in the body.

Clinical effectiveness and DHT production

The relationship between SRD5A2 activity and androgenic potency is well-established in clinical research.

• Enzymatic Activity: The rs523349 variant, characterized by a valine-to-leucine (V89L) substitution, is a significant determinant of enzyme performance. The leucine (L) allele is associated with a reduction in enzymatic activity of approximately 30% compared to the valine (V) allele.
• Androgen Metabolites: This reduction in activity is reflected in clinical markers, such as 3α-androstanediol glucuronide (3α-diol G), a metabolite used as a proxy for peripheral DHT production. Individuals with the LL genotype consistently show lower levels of these metabolites than those with the VV genotype.
• Clinical Correlates: Because DHT drives the growth of androgen-sensitive tissues, the VV genotype (higher activity) is linked to an increased risk of conditions like benign prostatic hyperplasia and aggressive prostate cancer, while the LL genotype appears to offer a degree of protection.

Mechanistic explanations

The biological mechanism underlying this claim is rooted in the structural biology of androgen receptors and enzyme kinetics.

• Androgen Potency: DHT is significantly more potent than testosterone due to its superior binding affinity for the androgen receptor (AR). Experimental data shows DHT binds to the AR with 2 to 10 times the affinity of testosterone and dissociates more slowly, leading to more sustained transcriptional activation.
• Molecular Conversion: The 5α-reductase type 2 enzyme utilizes NADPH to reduce the Δ4 double bond of testosterone. The V89L substitution in the enzyme's structure alters its catalytic efficiency, thereby regulating the local and systemic concentration of DHT.

Bottom line

The SRD5A2 gene is the primary blueprint for 5α-reductase type 2, the enzyme responsible for creating the highly potent androgen DHT. The rs523349 variant is a functional modulator of this process; the V-allele promotes higher enzyme activity and DHT levels, while the L-allele results in lower activity and reduced DHT production.